Heart drug dosing study aims to protect fontan Patients' livers

NCT ID NCT06324396

Recruiting now Knowledge-focused Sponsor: Children's Mercy Hospital Kansas City Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study looks at how liver congestion and scarring affect the way the body processes two common drugs, sildenafil and pravastatin, in people with Fontan circulation. Researchers will give a single dose of each drug to 15 participants aged 8 and older and measure drug levels in the blood. The goal is to improve dosing guidelines for this unique patient group.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Sildenafil and Pravastatin
What this could lead to: If successful, this could help doctors prescribe safer, more effective doses of common drugs for people with Fontan circulation.
What could go wrong: This is a very small, early-phase study with only 15 participants, so results may not apply to everyone. It only looks at drug levels, not long-term health outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FONTAN CIRCULATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Fontan-associated liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FONTAN CIRCULATION

Contacts and locations

Locations

Children's Mercy Hospital
RECRUITING

Kansas City, Missouri, 64108, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.